Schizophrenia-like psychosis and Gitelman syndrome: a case report and literature review

Bing Pan1, Lijun Mou2*, Huichun Li1, Weibo Liu1 and Ying Hu2

Abstract

Introduction: Gitelman syndrome (GS) is a rare inherited tubular disorder which is characterized by hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria. Here, we report a case of schizophrenia-like psychosis concomitant with GS and related literatures are reviewed.

Case description: An 18-year-old male patient with 1-week history of auditory hallucinations, sense of insecurity, delusions of reference and feelings of being followed and controlled by others unknown, insomnia was admitted to Psychiatry department in December, 2013. Hypokalemia and hypomagnesemia were noted. He was diagnosed as schizophrenia-like psychosis. Treatment with paliperidone at the dose of 6 mg/day and magnesium and potassium supplementations was commenced. However, electrolyte disturbances failed to improve following psychosis remission. Therefore, other underlying diseases resulting in electrolyte disturbances were suspected. Along with hypokalemia and hypomagnesemia, additional investigation showing metabolic alkalosis, hypocalciuria, renal loss of potassium, were consistent with GS. Gene analysis revealed this patient carried out c. 2687 G > A homozygous mutation of exon 23 in the SLC12A3 gene which led to p.Arg896Gln. Eventually, GS was identified. Thus, additional spironolactone (40 mg/day) combined with increased doses of oral potassium chloride sustained-release tablets (3.0 g/day) and potassium magnesium aspartate (0.3 g/day) were administered. During next half a year, fatigue resolved, paliperidone gradually tapered and eventually discontinued while psychosis maintained complete remission. His serum potassium was near normal (3.2–3.5 mmol/L), hypomagnesemia significantly improved (0.57–0.67 mmol/L).

Discussion and evaluation: Electrolyte abnormalities secondary to GS might cause or contribute to development of neuropsychiatric symptoms. In turn, hypokalemia was common among acute psychiatric inpatients. As a consequence, when concomitant with psychosis, GS was readily concealed.

Conclusion: Electrolyte disturbances are common in acute psychiatric patients. However, when electrolyte disturbances are not improved following psychosis remission, other underlying diseases such as GS should be considered.

Keywords: Gitelman syndrome, Hypokalemia, Hypomagnesemia, Schizophrenia-like psychosis

Background

Gitelman syndrome (GS) is a rare autosomal recessive tubular disorder first described by Gitelman et al. (1966). It is caused by mutation of SLC12A3 gene, which encodes the Sodium/Chloride co-transporter (NCCT) in the distal convoluted tubule (Simon et al. 1996). GS is characterized by hypokalemia, metabolic alkalosis, hypomagnesemia and hypocalciuria. The majority of patients with GS do not present with symptoms until late childhood or adulthood (Naesens et al. 2004). Electrolyte abnormalities secondary to GS may cause or contribute to development of neuropsychiatric symptoms. In turn, hypokalemia is common among acute psychiatric patients (Lam et al. 2009). As a consequence, when concomitant with psychosis, GS is readily concealed. Here...
we report a case of schizophrenia-like psychosis in a 18-year-old boy with coexisting GS.

**Case description**

An 18-year-old boy with 1-week history of auditory hallucinations, sense of insecurity, delusions of reference and feelings of being followed and controlled by others unknown, insomnia was admitted to Psychiatry department in December, 2013. He often heard many boys and girls commenting on him and criticising him sometimes. He suspected people were always discussing him and doing harm to him. These symptoms mentioned above made him sometimes just stare blankly, feel nervous, restless, tired, irritable, afraid of going outside. Insomnia subsequently developed. He was previously healthy and had no remarkable family history. He was enrolled in a high school. He did not smoke, drink alcohol or use illicit drugs. After admission to the hospital, physical examination was normal. On mental state examination, the patient was oriented and cooperative. Positive and Negative Symptoms Scale (PANSS) scored 95 which indicated he was in acute psychosis. His full scale of Weschler Adult Intelligence was 98 which indicated his intelligence was normal. His electrocardiogram, brain magnetic resonance imaging were normal. The laboratory investigations showed hypokalemia (3.17 mmol/L), hypomagnesemia (0.48 mmol/L).

According to his symptoms and investigations, the patient was diagnosed with schizophrenia-like psychosis and was treated with paliperidone at the dose of 6 mg/day and magnesium and potassium supplementations. Two weeks later, anxiety ameliorated, quality of sleep improved, hallucination and delusion resolved. The PANSS scores decreased to 41. His serum potassium increased to 3.23 mmol/L, magnesium level was still at 0.48 mmol/L. His electrolyte disturbances were thought to be caused by acute psychosis and were expected to recover soon, the patient was discharged with oral potassium and magnesium supplementations.

During the regular following up, the patient felt a little fatigue as before while his psychosis maintained complete remission. Two weeks later after discharge, laboratory studies showed worsened hypokalemia (2.99 mmol/L) and hypomagnesemia (0.49 mmol/L) despite potassium and magnesium supplementations. He had no history of diuretic, laxative and licorice intake, no episode of anorexia, vomiting and diarrhea. Considering that his psychosis and other common conditions failed to explain his electrolyte disturbances, we consulted a nephrologist who suspected this patient might had GS, further examinations were subsequently ordered. The results of hypokalemia, hypomagnesemia, metabolic alkalosis, hypocaliuria were consistent with GS (Table 1).

| Variable                          | Reference range     |
|-----------------------------------|---------------------|
| Sodium (mmol/L)                   | 138.4 135 to 145    |
| Potassium (mmol/L)                | 2.99 3.5 to 5.5     |
| Urea (mmol/L)                     | 4.10 2.80 to 7.2    |
| Creatinine (μmol/L)               | 59 53 to 133        |
| Fasting blood glucose (mmol/L)    | 4.51 3.89 to 6.11   |
| Calcium (mmol/L)                  | 2.37 2.08 to 2.60   |
| Phosphate (mmol/L)                | 1.31 0.81 to 1.45   |
| Magnesium (mmol/L)                | 0.49 0.73 to 1.06   |
| Albumin (g/L)                     | 52 35.0 to 52.0     |
| Uric acid (μmol/L)                | 436 208 to 428      |
| Alanine aminotransferase (U/L)    | 20 <45              |
| Aspartate aminotransferase (U/L)  | 21 <35              |
| Intact parathyroid hormone (pg/ml)| 26.86 15.00 to 65.00|
| h-TSH (mIU/L)                     | 4.17 0.35 to 4.94   |
| Growth hormone (ng/mL)            | <0.05 <4.80         |
| Aldosterone (standing, ng/L)      | 192.49 65.00 to 296.00|
| Plasma rennin activity (standing, μg/L/h)| 0.29 0.93 to 6.56 |

In order to verify this diagnosis, gene analysis was performed. Genomic DNA was isolated and purified from peripheral blood of the subject and used for polymerase chain reaction (PCR) amplification of individual exons of the SLC12A3 gene. Twenty-six pairs of oligonucleotide primers were generated to amplify all 26 exons and flanking intronic regions. PCRs were performed in a 50 μL volume containing 1 μL genomic DNA, 2 μL primers, 1 μL deoxyribonucleotide triphosphate(dNTP), and 5 μL 10 × 9 Taq buffer, 5 μL MgCl2, 2.5 U Taq enzyme, and 35.5 μL ddH2O. PCR was performed using standard conditions with an initial denaturation step at 95 °C for 3 min, subsequently followed by 35 cycles with denaturation at 94 °C for 30 s, annealing at 55–60 °C for 35 s and elongation at 72 °C for 40–50 s. Sanger direct sequencing was performed on an ABI 3730XL automated DNA sequencer (Applied Biosystems Division, Life Technologies, CA, USA) by Sangon Biotech Shanghai Co., (Shanghai, China). GenBank Accession Number NC_000016, was used as
reference sequences. The numbering of a nucleotide starts
at the first adenine of the translation initiation codon. This
patient carried out c. 2687 G > A homozygous mutation
of exon 23 in the \textit{SLC12A3} gene which led to p.Arg896Gln
which was already known as pathogenic mutation in the
previous report (Kurschat et al. 2003) (Fig. 1).

Eventually, the diagnosis of GS was established. Thus,
additional spironolactone (40 mg/day) combined with
increased doses of oral potassium chloride sustained-
release tablets (3.0 g/day) and potassium magnesium
aspartate (0.3 g/day) were administered. During next half
a year, fatigue resolved, paliperidone gradually tapered
and eventually discontinued while psychosis maintained
complete remission. His serum potassium was near nor-
mal (3.2–3.5 mmol/L), hypomagnesemia significantly
improved (0.57–0.67 mmol/L).

\textbf{Discussion and evaluation}

This patient with classical psychotic symptoms was diag-
nosed as schizophrenia-like psychosis at presentation.
Hypokalemia and hypomagnesemia were noted. How-
ever, electrolyte disturbances failed to improve following
psychosis remission which prompted us to suspect the
electrolyte disturbances were caused by other underlying
diseases. Eventually, GS was identified by gene analysis.
To our knowledge, this is the first report of schizophre-
nia-like psychosis concomitant with GS.

GS is a rare disease which is initially considered as a
mild type of the salt-losing tubular disorder (Sampath-
kumar et al. 2010). A later study demonstrated that GS
is not an asymptomatic disease. It adversely affects
quality of life in patients with GS principally resulted
from secondary electrolyte abnormalities, to at least the
same degree as more significant diseases like hyperten-
sion, diabetes, and cardiac conditions (Cruz et al. 2001).
Hypokalaemia alone was associated with the develop-
ment of central pontine myelinolysis which produced
psychiatric symptoms such as changes in the level of con-
sciousness and behaviour or cognitive dysfunction (Bahr
et al. 1990; Sugimoto et al. 2003). Hypomagnesemia also
led to clinically significant signs and symptoms when
serum levels fall below 0.5 mmol/L (1.2 mg/dL). Clinical
manifestations of hypomagnesemia that promptly led to
medical attention involve neuromuscular hyperexcitabil-
ity that may range from tremors, fascicula-tion, tetany, to
convulsions, and neuropsychiatric disturbances includ-
ing apathy, delirium, and even coma (Pham et al. 2014).
Therefore, psychosis and electrolyte abnormalities sec-
dory to GS manifested overlapping symptoms which
would conceal the coexistence of GS.

In turn, hypokalemia was common among acute psy-
chiatric patients (27.7 %), both agitation and the use of
antipsychotics were postulated to contribute to the high
prevalence of hypokalemia among acutely ill psychiatric
patients (Lam et al. 2009). Antipsychotics were found to
block the potassium efflux channel and prohibit intracel-
luar potassium from shifting into the extracellular com-
artment, they have been reported to cause hypokalemia
when being taken in excess or overdose (Malik et al.
2005). Hypokalemia already developed before the usage
of paliperidone and persisted after discontinuation, so
hypokalemia was not caused by antipsychotics in this
patient. Agitation was postulated to stimulate the surge
of serum adrenaline, which via the over-stimulation of

Fig. 1 The mutated sequence of NCCT polymerase chain reaction (PCR) fragment. The \textcolor{red}{red circle} indicates a homozygous c.2687 G > A mutation of exon 23 in \textit{SLC12A3} which led to p.Arg896Gln
beta-adrenaline receptors, caused influx of potassium into cells (Lam et al. 1999). Under this condition, hypokalemia might recover spontaneously following agitation remission. At first, we considered his electrolyte disturbance was only caused by agitation. But the electrolyte disturbances did not resolve after his psychosis remission which prompted us to investigate other causes. Eventually, the diagnosis of GS was established. With intensive potassium and magnesium supplementation and additional spironolactone, electrolyte disturbances significantly improved.

**Conclusion**

Conclusively, electrolyte disturbances are common in acute psychiatric patients. However, when electrolyte disturbances are not improved following psychosis remission, other underlying diseases such as GS should be considered.

**Abbreviations**

GS: gitelman syndrome; NCCT: sodium/chloride co-transporter; PCR: polymerase chain reaction; PANSS: Positive and Negative Symptoms Scale.

**Authors’ contributions**

BP took part in the collection of materials of the patient and drafted the manuscript. HCL and WBL was involved in the treatment and final diagnosis of the patient. YH participated the analysis of the patient sample. LJM wrote part of the manuscript. All authors read and approved the final manuscript.

**Author details**

1 Department of Psychiatry, Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, Zhejiang, China.

2 Department of Nephrology, Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, Zhejiang, China.

**Competing interests**

This work was supported by research Grants from the Medical Science and Technology Projects of Zhejiang Province, China (2015KYA104).

**Consent for publication**

The patient and his father has consented the use of patient’s medical and personal information in this case report.

**Received**: 4 January 2016  **Accepted**: 15 June 2016  **Published online**: 24 June 2016

**References**

Bahr M, Sommer N, Petersen D, Wietholter H, Dichgans J (1990) Central pontine myelinolysis associated with low potassium levels in alcoholism. J Neurol 237:275–276

Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB, Gy Yale et al (2001) Gitelman’s syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 59:710–717

Gitelman HJ, Graham JB, Welt LG (1966) A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 79:221–235

Kurschat C, Heering P, Grabensee B (2003) Gitelman’s syndrome: an important differential diagnosis of hypokalemia. Dtsch Med Wochenschr 128:1225–1228

Lam RW, Carter D, Misri S, Kuan AJ, Yatham LN, Zis AP (1999) A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 86:185–192

Lam MH, Chau SW, Wing YK (2009) High prevalence of hypokalemia in acute psychiatric inpatients. Gen Hosp Psychiatry 31:262–265

Malik AR, Wolf PK, Ravasia S (2005) Hypokalemia from risperidone and quetiapine overdose. Can J Psychiatry 50:76

Naens S, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D (2004) Bartter’s and Gitelman’s Syndromes: from Gene to Clinic. Nephron Physiol 96:p65–p78

Pham PC, Pham PA, Pham SV, Pham PT, Pham PM, Pham PT (2014) Hypomagnesemia: a clinical perspective. Int J Nephrol Renovasc Dis 7:219–230

Sampathkumar K, Muralidharan U, Kannan A, Ramakrishnan M, Ajeshkumar R (2010) Childhood Bartter’s syndrome: an Indian case series. Indian J Nephrol 20:207–210

Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM et al (1996) Gitelman’s variant of Bartter’s syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 12:24–30

Sugimoto T, Murata T, Omori M, Wada Y (2003) Central pontine myelinolysis associated with hypokalemia in anorexia nervosa. J Neurol Neurosurg Psychiatry 74:353–355

**Submit your next manuscript at** springeropen.com